共 109 条
[1]
Sun CC(2005)Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer Support Care Cancer 13 219-227
[2]
Bodurka DC(2005)Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting Nat Clin Pract Oncol 2 196-201
[3]
Weaver CB(1997)Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 103-109
[4]
Rasu R(2006)American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932-2947
[5]
Wolf JK(2006)New antiemetic drugs Ann Oncol 17 96-100
[6]
Bevers MW(2007)Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations Oncologist 12 1143-1150
[7]
Smith JA(2001)Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone J Clin Oncol 19 1759-1767
[8]
Wharton JT(2003)The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group J Clin Oncol 21 4112-4119
[9]
Rubenstein EB(2003)Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 3090-3098
[10]
Oo TH(2005)Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822-2830